263 related articles for article (PubMed ID: 21948476)
1. Exploring host factors that impact reovirus replication, dissemination, and reovirus-induced cell death in cancer versus normal cells in culture.
Shmulevitz M; Lee PW
Methods Mol Biol; 2012; 797():163-76. PubMed ID: 21948476
[TBL] [Abstract][Full Text] [Related]
2. Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer.
Shmulevitz M; Marcato P; Lee PW
Oncogene; 2005 Nov; 24(52):7720-8. PubMed ID: 16299532
[TBL] [Abstract][Full Text] [Related]
3. Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release.
Marcato P; Shmulevitz M; Pan D; Stoltz D; Lee PW
Mol Ther; 2007 Aug; 15(8):1522-30. PubMed ID: 17457318
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release.
Garant KA; Shmulevitz M; Pan L; Daigle RM; Ahn DG; Gujar SA; Lee PW
Oncogene; 2016 Feb; 35(6):771-82. PubMed ID: 25961930
[TBL] [Abstract][Full Text] [Related]
5. Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants.
Mohamed A; Johnston RN; Shmulevitz M
Viruses; 2015 Dec; 7(12):6251-78. PubMed ID: 26633466
[TBL] [Abstract][Full Text] [Related]
6. Modification of mammalian reoviruses for use as oncolytic agents.
Van Den Wollenberg DJ; Van Den Hengel SK; Dautzenberg IJ; Kranenburg O; Hoeben RC
Expert Opin Biol Ther; 2009 Dec; 9(12):1509-20. PubMed ID: 19916732
[TBL] [Abstract][Full Text] [Related]
7. Reovirus and tumor oncolysis.
Kim M; Chung YH; Johnston RN
J Microbiol; 2007 Jun; 45(3):187-92. PubMed ID: 17618222
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in the Most Oncolytic Reovirus Strain Confer Enhanced Cell Attachment, Transcription, and Single-Step Replication Kinetics.
Mohamed A; Smiley JR; Shmulevitz M
J Virol; 2020 Jan; 94(4):. PubMed ID: 31776267
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic viral therapy using reovirus.
Thirukkumaran C; Morris DG
Methods Mol Biol; 2009; 542():607-34. PubMed ID: 19565924
[TBL] [Abstract][Full Text] [Related]
10. The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors.
Kapadia R; Coffey MC
Methods; 2010 Dec; 52(4):301-6. PubMed ID: 20801221
[TBL] [Abstract][Full Text] [Related]
11. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of oncolytic reovirus against human breast cancer cells.
Hata Y; Etoh T; Inomata M; Shiraishi N; Nishizono A; Kitano S
Oncol Rep; 2008 Jun; 19(6):1395-8. PubMed ID: 18497942
[TBL] [Abstract][Full Text] [Related]
13. The use of monoreassortants and reverse genetics to map reovirus lysis of a ras-transformed cell line.
Roner MR; Mutsoli C
J Virol Methods; 2007 Feb; 139(2):132-42. PubMed ID: 17049626
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic virotherapy for cancer treatment: challenges and solutions.
Davis JJ; Fang B
J Gene Med; 2005 Nov; 7(11):1380-9. PubMed ID: 16025557
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors.
Rodríguez Stewart RM; Berry JTL; Berger AK; Yoon SB; Hirsch AL; Guberman JA; Patel NB; Tharp GK; Bosinger SE; Mainou BA
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511390
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma.
Pandha HS; Heinemann L; Simpson GR; Melcher A; Prestwich R; Errington F; Coffey M; Harrington KJ; Morgan R
Clin Cancer Res; 2009 Oct; 15(19):6158-66. PubMed ID: 19773377
[TBL] [Abstract][Full Text] [Related]
17. Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus.
Puhlmann J; Puehler F; Mumberg D; Boukamp P; Beier R
Oncogene; 2010 Apr; 29(15):2205-16. PubMed ID: 20101224
[TBL] [Abstract][Full Text] [Related]
18. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
Fournier P; Bian H; Szeberényi J; Schirrmacher V
Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic Viral Therapy Using Reovirus.
Thirukkumaran C; Morris DG
Methods Mol Biol; 2015; 1317():187-223. PubMed ID: 26072409
[TBL] [Abstract][Full Text] [Related]
20. Exploring Reovirus Plasticity for Improving Its Use as Oncolytic Virus.
Kemp V; Hoeben RC; van den Wollenberg DJ
Viruses; 2015 Dec; 8(1):. PubMed ID: 26712782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
